Cardiovascular implications of SARS-CoV-2 infection : A literature review
In December 2019, a new strain of the SARS-CoV-2 coronavirus was reported in Wuhan, China, which produced severe lung involvement and progressed to respiratory distress. To date, more than seventeen million confirmed cases and more than half a million died worldwide from COVID-19. Patients with cardiovascular disease are more susceptible to contracting this disease and presenting more complications. We did a literature search on the association of cardiovascular disease and COVID-19 in databases such as Scopus, PubMed/MEDLINE, and the Cochrane Library. The purpose of this review is to provide updated information for health professionals who care for patients with COVID-19 and cardiovascular disease, given that they have a high risk of complications and mortality. Treatment with angiotensin-converting enzyme inhibitors and receptor blockers is controversial, and there is no evidence not to use these medications in patients with COVID-19. Regarding treatment with hydroxychloroquine associated or not with azithromycin, there is evidence of a higher risk with its use than clinical benefit and decreased mortality. Likewise, patients with heart failure are an important risk group due to their condition per se. Patients with heart failure and COVID-19 are a diagnostic dilemma because the signs of acute heart failure could be masked. On the other hand, in patients with acute coronary syndrome, the initial therapeutic approach could change in the context of the pandemic, although only based on expert opinions. Nonetheless, many controversial issues will be the subject of future research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Medwave - 20(2020), 7 vom: 28. Aug., Seite e8008 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Implicaciones cardiovasculares de la infección por SARS-CoV-2: revisión de literatura |
|---|
| Beteiligte Personen: |
García-Saavedra, Mario B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.09.2020 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5867/medwave.2020.07.8008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314503331 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314503331 | ||
| 003 | DE-627 | ||
| 005 | 20231225152854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.5867/medwave.2020.07.8008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314503331 | ||
| 035 | |a (NLM)32877391 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a García-Saavedra, Mario B |e verfasserin |0 (orcid)0000-0002-3534-5119 |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular implications of SARS-CoV-2 infection |b A literature review |
| 246 | 3 | 3 | |a Implicaciones cardiovasculares de la infección por SARS-CoV-2: revisión de literatura |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In December 2019, a new strain of the SARS-CoV-2 coronavirus was reported in Wuhan, China, which produced severe lung involvement and progressed to respiratory distress. To date, more than seventeen million confirmed cases and more than half a million died worldwide from COVID-19. Patients with cardiovascular disease are more susceptible to contracting this disease and presenting more complications. We did a literature search on the association of cardiovascular disease and COVID-19 in databases such as Scopus, PubMed/MEDLINE, and the Cochrane Library. The purpose of this review is to provide updated information for health professionals who care for patients with COVID-19 and cardiovascular disease, given that they have a high risk of complications and mortality. Treatment with angiotensin-converting enzyme inhibitors and receptor blockers is controversial, and there is no evidence not to use these medications in patients with COVID-19. Regarding treatment with hydroxychloroquine associated or not with azithromycin, there is evidence of a higher risk with its use than clinical benefit and decreased mortality. Likewise, patients with heart failure are an important risk group due to their condition per se. Patients with heart failure and COVID-19 are a diagnostic dilemma because the signs of acute heart failure could be masked. On the other hand, in patients with acute coronary syndrome, the initial therapeutic approach could change in the context of the pandemic, although only based on expert opinions. Nonetheless, many controversial issues will be the subject of future research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a coronavirus infections | |
| 650 | 4 | |a coronavirus | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Rosales-Gutiérrez, Renzo R |e verfasserin |0 (orcid)0000-0002-6751-2989 |4 aut | |
| 700 | 1 | |a Valverde, Esmeralda |e verfasserin |0 (orcid)0000-0003-0640-9731 |4 aut | |
| 700 | 1 | |a Chumbes-Aguirre, Maryuri |e verfasserin |0 (orcid)0000-0002-8964-283X |4 aut | |
| 700 | 1 | |a Alvarado, Ricardo |e verfasserin |0 (orcid)0000-0001-5559-6815 |4 aut | |
| 700 | 1 | |a Polo, Robert |e verfasserin |0 (orcid)0000-0002-4886-2166 |4 aut | |
| 700 | 1 | |a Azañero, Rubén |e verfasserin |0 (orcid)0000-0001-5661-7841 |4 aut | |
| 700 | 1 | |a Chávez, Carlos |e verfasserin |0 (orcid)0000-0001-7237-8174 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medwave |d 2014 |g 20(2020), 7 vom: 28. Aug., Seite e8008 |w (DE-627)NLM241622328 |x 0717-6384 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:7 |g day:28 |g month:08 |g pages:e8008 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5867/medwave.2020.07.8008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 7 |b 28 |c 08 |h e8008 | ||